Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18548711 | 0.90 | CSF1R (0.54) | LMNARXFP1GSK3ATP53MAPT | |
| SCHEMBL18548611 | 0.89 | LMNA (0.53) | LMNARXFP1GSK3ATP53MAPT | |
| SCHEMBL29660162 | 0.89 | LMNA (0.53) | LMNARXFP1GSK3ATP53MAPT | |
| SCHEMBL18548706 | 0.86 | LMNA (0.48) | LMNARXFP1GSK3ATP53MAPT | |
| SCHEMBL29660246 | 0.86 | LMNA (0.48) | LMNARXFP1GSK3ATP53MAPT | |
| SCHEMBL18548684 | 0.82 | LMNA (0.45) | LMNARXFP1TP53MAPTSMN1; SMN2 | |
| SCHEMBL29660177 | 0.82 | LMNA (0.45) | LMNARXFP1TP53MAPTSMN1; SMN2 | |
| SCHEMBL18548652 | 0.80 | LMNA (0.45) | LMNARXFP1TP53MAPTSMN1; SMN2 | |
| SCHEMBL29660199 | 0.80 | LMNA (0.45) | LMNARXFP1TP53MAPTSMN1; SMN2 | |
| SCHEMBL23053052 | 0.80 | TP53 (0.57) | LMNARXFP1TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340796-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2021-04-21 | — | — | EP | claimed |
| US-10765764-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2020-09-08 | — | — | US | claimed |
| US-20190167821-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2019-06-06 | — | — | US | claimed |
| US-10137211-B2 | Probes for imaging Huntingtin protein | CHDI FOUNDATION, INC. (US) | 2018-11-27 | — | — | US | claimed |
| US-20170056535-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-03-02 | — | — | US | claimed |
| US-12083108-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | CHDI FOUNDATION, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20220409600-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11389438-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | CHDI FOUNDATION, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11344637-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11344637-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3340796-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20210060187-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10765764-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200276176-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | CHDI FOUNDATION, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20190167821-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190167821-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10137211-B2 | Probes for imaging Huntingtin protein | CHDI FOUNDATION, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170056535-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170056535-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170056535-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344637-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | LMNA 2021/4885RXFP1 660/4885GSK3A 4184/4885 |
| US-20210060187-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | LMNA 2021/4885RXFP1 660/4885GSK3A 4184/4885 |
| US-12083108-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | HTT, HYPK, UBQLN2 | LMNA 3285/4885RXFP1 4566/4885GSK3A 1148/4885 |
| US-11389438-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | HTT, HYPK, UBQLN2 | LMNA 3285/4885RXFP1 4566/4885GSK3A 1148/4885 |
| US-20200276176-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | HTT, HYPK, UBQLN2 | LMNA 3285/4885RXFP1 4566/4885GSK3A 1148/4885 |
| US-20190167821-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | LMNA 2021/4885RXFP1 660/4885GSK3A 4184/4885 |
| US-20170056535-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | LMNA 2021/4885RXFP1 660/4885GSK3A 4184/4885 |
| US-20220409600-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | HTT, HYPK, UBQLN2 | LMNA 3285/4885RXFP1 4566/4885GSK3A 1148/4885 |
| US-10765764-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | LMNA 2021/4885RXFP1 660/4885GSK3A 4184/4885 |
| US-10137211-B2 | Probes for imaging Huntingtin protein | HTT, HYPK, FABP7 | LMNA 1600/4885RXFP1 727/4885GSK3A 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.